Three-dimensional nanostructured substrates enable dynamic detection of ALK-rearrangement in circulating tumor cells from treatment-naive patients with stage III/IV lung adenocarcinoma

Table 2 Numbers and percentages of ALK-rearranged cells in tumor and in CTC of ALK-negative patients

Patient	Sex	Age (y/o)	Smoking status (y/o)	Adenocarcinoma subtype	Clinical stage	Tumor		CTCs by NanoVelcro			CTC number by CellSearch (7.5 ml)
Patient	Sex	Age (y/o)	Smoking status (y/o)	Adenocarcinoma subtype	Clinical stage	Biopsy origin	% of rearranged cells	Rearranged CTCs (per ml)	% of rearranged CTCs	Total CTCs (per ml)	CTC number by CellSearch (7.5 ml)
PN1	M	39	10	Mucinous	IV	Bone (MS)	0	2	7	27	23
PN2	F	47	0	Solid	III	Lung (PT)	0	0	0	14	36
PN3	F	71	0	Papillary	III	Lung (PT)	0	0	0	7	14
PN4	F	52	0	Solid	IV	Pleura (MS)	0	0	0	28	39
PN5	M	67	30	Papillary	IV	Node (MS)	0	1	5	21	71
PN6	F	54	4	Solid	III	Node (MS)	0	1	6	16	49
PN7	M	45	0	Mucinous	IV	Brain (MS)	0	0	0	32	53
PN8	M	37	0	Solid	IV	Lung (PT)	0	2	6	36	57
PN9	F	75	0	Solid	IV	Pleura (MS)	N/A	0	0	25	43
PN10	F	58	0	Mucinous	III	Lung (PT)	0	0	0	21	38
PN11	F	63	0	Solid	III	Pleura (MS)	0	0	0	15	57
PN12	M	54	27	Mucinou	IV	Node (MS)	0	1	3	35	29
PN13	M	77	0	Solid	III	Lung (PT)	0	0	0	19	0
PN14	F	39	3	Solid	IV	Node (MS)	0	0	0	42	21
PN15	F	53	0	Solid	IV	Bone (MS)	0	2	5	37	69
PN16	F	61	0	Mucinous	III	Lung (PT)	0	0	0	6	0
PN17	M	60	0	Papillary	IV	Node (MS)	0	0	0	38	57
PN18	M	71	47	Solid	III	Lung (PT)	0	0	0	23	39
PN19	F	47	0	Mucinou	III	Lung (PT)	0	0	0	20	41
PN20	F	63	0	Papillary	IV	Bone (MS)	0	0	0	43	71

ALK anaplastic lymphoma kinase, CTC circulating tumor cell, M male, MS metastatic site, N/A not available, PT primary tumor

ISSN: 1479-5876